Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment.
(50/139)
Bowel perforation is a rare but life-threatening complication of bevacizumab, a new anticancer treatment. Patients with bowel perforation usually present with acute abdominal symptoms. Here a case history is presented to highlight a pancreatic cancer patient on bevacizumab chemotherapy who developed empyema as the first manifestation of gastric perforation. This unusual presentation warns physicians that bevacizumab-related bowel perforation can arise as a thoracic complication, without typical gastrointestinal manifestations, in an advanced cancer patient. (+info)
Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah.
(51/139)
Malignant mesothelioma associated with chronic empyema with elevation of serum CYFRA19: A case report.
(52/139)
Malignant neoplasms are reported to occur with long-standing tuberculous pleuritis or chronic empyema. During the clinical course of chronic empyema, subjective symptoms such as chest pain and deterioration of dyspnea and abnormal clinical signs such as increased abnormal chest shadows have frequently been found. Though difficult, differentiating the occurrence of malignant tumors from worsening chronic inflammation is crucial. We report here a case of malignant mesothelioma associated with chronic empyema with elevation of serum CYFRA19. (+info)
Empyema due to a highly transmissible Pseudomonas aeruginosa strain in an adult cystic fibrosis patient.
(53/139)